{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2767","value":"16.382"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"10mg daily dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.8396","value":"4.700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"5mg daily dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"A pre-dose blood sample at day 29 was collected to determine the exposure of everolimus at the steady-state pre-dose concentration (Cmin). Cmin is provided for participants randomized to everolimus+BSC who received 10mg of everolimus daily and also for participants randomized to everolimus+BSC who received 5mg of everolimus daily which was required for a number of participants in the study experiencing adverse events requiring dose modifications","dispersionType":"Standard Deviation","groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"OG000","title":"Everolimus + BSC"}],"paramType":"MEAN","populationDescription":"All patients who received at least one dose of the study drug with evaluable blood samples for this endpoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose at Day 29.","title":"Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter (ng/mL)"}